Abstract
In healthy volunteers and patients with severe chronic occlusive arterial diseases, Urokinase was given intravenously. There is a dose dependend decrease in fibrinogen concentration, whole blood viscosity, plasma viscosity and red cell aggregability whereas red cell filtrability remains unchanged. This influence of Urokinase on the flow properties of blood could be responsible for some clinical improvements in patients with vascular disorders even when a thrombolytic effect is not yet detectable. Long term systemic low dose Urokinase treatment could be a promising approach in severe stages of ischemic diseases.
Get full access to this article
View all access options for this article.